MRI Guided HIFU for Palliation of Painful Skeletal Metastases in Children

• Sponsor: The Hospital for Sick Children (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT02616016
• Collaborator: Sunnybrook Health Sciences Centre (Other)
• Enrollment: 10
• Location: 1
• Arm: 1
• Duration (Months): 96
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

The Philips Sonalleve MR-HIFU system is expected to be effective in reducing pain intensity and/or reducing analgesic use in patients with painful uncomplicated bone metastases. No serious adverse effects are expected to result from this treatment.

Condition or Disease	Intervention/Treatment	Phase
Bone Metastases; Pain	Device: MRI Guided High Intensity Focused Ultrasound	N/A

Detailed Description

The objective of this study is to determine if MR-guided high intensity focused ultrasound (MR-HIFU) is an effective technique for alleviating the pain associated with bone metastases in paediatric cancer patients. This technique meant to be an adjunct therapy to the standard-of-care, which includes radiation therapy and chemotherapy. Safety of the technique will be assessed through evaluating non-targeted heating using MRI-based temperature mapping, and inspecting patients post-treatment for skin burns. or other signs of serious adverse events. Efficacy of the technique will be assessed by evaluating/recording patients observed pain, quality of life, and pain medication usage both before and up to 3 months following treatment.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases in Children - A Pilot Study
• Study Start Date: Apr 1, 2014
• Anticipated Primary Completion Date: Apr 1, 2022
• Anticipated Study Completion Date: Apr 1, 2022

Arms and Interventions

Arm

Intervention/Treatment

Other: MRI guided High Intensity Focused Ultrasound Treatment Intervention Group The interventional radiologist will locate the target tissue and mark the volume to be treated using MRI images. The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan. An individual treatment sonication will last approximately 30 seconds.

Device: MRI Guided High Intensity Focused Ultrasound; Target treatment of bone metastases using High Intensity Focused Ultrasound

Outcome Measures

Primary Outcome Measures

1. Change in pain intensity scores from baseline as measured on pain diaries. [2, 7, 14, 30 and 90 days following treatment]

   As measured on the pain diaries before and at day 2, 7, 14, 30 and 90 days following treatment.

Secondary Outcome Measures

1. Improved patient quality of life after MR-HIFU using a quality of life questionnaire. [2, 7, 14, 30 and 90 days post treatment]

   Using age appropriate quality of life questionnaire that involves interviewing patient and/or parent/guardian before and 2, 7, 14, 30 and 90 days post treatment.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 5 Years to 17 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• able to give informed consent

• weight <140 kg (requirement to fit safely on top of the HIFU table and inside MRI

• any radiologic evidence of bone metastases from any solid tumor (neuroblastoma, osteosarcoma, soft tissue sarcoma, or any other solid tumor metastases).

• pain specifically at the site of interest (target lesion)

• pain score for target lesion >/ = 4 (indicating at least moderate pain) on an age-appropriate 0-10 point scale

• Target lesion in uncomplicated (ie no fracture / spinal cord compression /cauda equine syndrome/ soft tissue component)

• Available 3D MRI image of the target lesion (or be able to obtain one in a clinically feasible amount of time as part of the baseline investigational stage.)

• Proposed MR-HIFU treatment date >/= 2 weeks from most recent treatment of target tumour or systems chemotherapy

• Proposed MR-HIFU treatment date >/= 1 week after administration of steroids for pain flare

Exclusion Criteria:

• Unable to characterize pain specifically at the site of interest (target lesion).

• Pregnant / nursing females

• Target lesion is complicated (ie pressure of one fracture /spinal cord compression/cauda equine syndrome/soft tissue component)

• Target lesion < 1cm from nerve bundles/ bladder/bowel

• Target lesion in contact with hollow viscera

• Target lesion located in skull, spine (excluding sacrum which is allowed) or sternum.

• scar along proposed HIFU beam path.

• Orthopaedic implant along proposed HIIFU beam path or at site of target lesion.

• Active infection.

• Contradiction to general anesthesia or or gadolinium MRI contrast agent.

• Requirement for general anaesthesia for non -HIFU related MRI scans.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Hospital for Sick Children	Toronto	Ontario	Canada	M5G 1X8

Sponsors and Collaborators

• The Hospital for Sick Children
• Sunnybrook Health Sciences Centre

Investigators

• Principal Investigator: James M Drake, FRCSC,FACS, The Hospital for Sick Children

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: James Drake, Neurosurgeon, The Hospital for Sick Children
• ClinicalTrials.gov Identifier: NCT02616016
• Other Study ID Numbers: 1000040604
• First Posted: Nov 26, 2015
• Last Update Posted: Jul 14, 2021
• Last Verified: Jul 1, 2021

• Additional relevant MeSH terms: Neoplasm Metastasis

Study Results

No Results Posted as of Jul 14, 2021